MedTrace Logo

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2026-05-14

No results posted yet for this study

Summary

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

Conditions

  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • NSCLC
  • RAS Mutation
  • MTAP Deletion
  • Lung Cancer
  • Pancreatic Cancer Metastatic
  • Thoracic Cancer

Interventions

DRUG

TNG462

MTA cooperative PRMT5 inhibitor

DRUG

RMC-9805

RAS(ON) G12D selective covalent inhibitor

DRUG

RMC-6236

RAS(ON) multi-selective inhibitor

DRUG

mFOLFIRINOX

Chemotherapy

DRUG

gemcitabine/nab-paclitaxel

Chemotherapy

Sponsors & Collaborators

  • Revolution Medicines, Inc.

    collaborator INDUSTRY

  • Tango Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Maxim Pimpkin, MD, PhD · Tango Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06922591 on ClinicalTrials.gov